Table 2.
Frequency of primary endpoint and censoring criteria by treatment arm
| Total (N = 198) | Valaciclovir (n = 97) | Placebo (n = 101) | |
|---|---|---|---|
| Met primary endpoint | 102 (51.5) | 47 (48.5) | 55 (54.5) |
| CD4 ≤350 cells/mm3 | 11 (5.56) | 6 (6.19) | 5 (4.95) |
| CD4 ≤350 cells/mm3 and cART initiation | 1 (0.51) | 1 (1.03) | 0 (0) |
| cART initiation | 90 (45.5) | 40 (41.2) | 50 (49.5) |
| Did not meet primary endpoint | 96 (48.5) | 50 (51.5) | 46 (45.5) |
| end of study | 61 (30.8) | 34 (35.1) | 27 (26.7) |
| withdrew consent | 19 (9.60) | 8 (8.25) | 11 (10.9) |
| lost to follow-up | 10 (5.05) | 5 (5.15) | 5 (4.95) |
| moved | 4 (2.02) | 1 (1.03) | 3 (2.97) |
| site withdrew | 2 (1.01) | 2 (2.06) | 0 (0) |
All values are n (%).